Stocks and Investing Stocks and Investing
Tue, November 2, 2021
Mon, November 1, 2021

Yatin Suneja Upgraded (ACAD) to Strong Buy and Held Target at $23 on, Nov 1st, 2021


Published on 2024-10-27 18:26:41 - WOPRAI, Yatin Suneja
  Print publication without navigation


Yatin Suneja of Guggenheim, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Held Target at $23 on, Nov 1st, 2021.

Yatin has made no other calls on ACAD in the last 4 months.



There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 2 agree with Yatin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeffrey Hung of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $20 on, Thursday, October 14th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $25 on, Thursday, August 5th, 2021


These are the ratings of the 2 analyists that currently disagree with Yatin


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $26 on, Thursday, August 5th, 2021
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $28 on, Thursday, August 5th, 2021
Contributing Sources